Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial

C S J Probert; S D Hearing; S Schreiber; T Kühbacher; S Ghosh; I D R Arnott; A Forbes

doi:10.1136/gut.52.7.998

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial

C S J Probert, S D Hearing, S Schreiber, T Kühbacher, S Ghosh, I D R Arnott, A Forbes

Research output: Contribution to journal › Article › peer-review

344 Citations (Scopus)

Abstract

Tumour necrosis factor production is increased in the mucosa of patients with active ulcerative colitis. The benefits of infliximab in Crohn's disease are established. We investigated its efficacy in ulcerative colitis.

Original language	English
Pages (from-to)	998-1002
Number of pages	5
Journal	Gut
Volume	52
Issue number	7
DOIs	https://doi.org/10.1136/gut.52.7.998
Publication status	Published - Jul 2003

Keywords

Adult
Anti-Inflammatory Agents
Antibodies, Monoclonal
C-Reactive Protein
Colitis, Ulcerative
Double-Blind Method
Drug Resistance
Female
Glucocorticoids
Humans
Immunosuppressive Agents
Male
Middle Aged
Quality of Life
Remission Induction
Treatment Outcome

Access to Document

10.1136/gut.52.7.998

Cite this

@article{2d0f66fb84fe4780b441b37f082ae58c,

title = "Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial",

abstract = "Tumour necrosis factor production is increased in the mucosa of patients with active ulcerative colitis. The benefits of infliximab in Crohn's disease are established. We investigated its efficacy in ulcerative colitis.",

keywords = "Adult, Anti-Inflammatory Agents, Antibodies, Monoclonal, C-Reactive Protein, Colitis, Ulcerative, Double-Blind Method, Drug Resistance, Female, Glucocorticoids, Humans, Immunosuppressive Agents, Male, Middle Aged, Quality of Life, Remission Induction, Treatment Outcome",

author = "Probert, {C S J} and Hearing, {S D} and S Schreiber and T K{\"u}hbacher and S Ghosh and Arnott, {I D R} and A Forbes",

year = "2003",

month = jul,

doi = "10.1136/gut.52.7.998",

language = "English",

volume = "52",

pages = "998--1002",

journal = "Gut",

issn = "0017-5749",

publisher = "BMJ Publishing Group",

number = "7",

}

TY - JOUR

T1 - Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial

AU - Probert, C S J

AU - Hearing, S D

AU - Schreiber, S

AU - Kühbacher, T

AU - Ghosh, S

AU - Arnott, I D R

AU - Forbes, A

PY - 2003/7

Y1 - 2003/7

N2 - Tumour necrosis factor production is increased in the mucosa of patients with active ulcerative colitis. The benefits of infliximab in Crohn's disease are established. We investigated its efficacy in ulcerative colitis.

AB - Tumour necrosis factor production is increased in the mucosa of patients with active ulcerative colitis. The benefits of infliximab in Crohn's disease are established. We investigated its efficacy in ulcerative colitis.

KW - Adult

KW - Anti-Inflammatory Agents

KW - Antibodies, Monoclonal

KW - C-Reactive Protein

KW - Colitis, Ulcerative

KW - Double-Blind Method

KW - Drug Resistance

KW - Female

KW - Glucocorticoids

KW - Humans

KW - Immunosuppressive Agents

KW - Male

KW - Middle Aged

KW - Quality of Life

KW - Remission Induction

KW - Treatment Outcome

U2 - 10.1136/gut.52.7.998

DO - 10.1136/gut.52.7.998

M3 - Article

C2 - 12801957

VL - 52

SP - 998

EP - 1002

JO - Gut

JF - Gut

SN - 0017-5749

IS - 7

ER -